The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Strontium ranelate for preventing and treating postmenopausal osteoporosis
Open accessAbstract
BACKGROUND: Strontium ranelate is a new treatment for osteoporosis therefore, its benefits and harms need to be known. OBJECTIVES: To determine the efficacy and safety of strontium ranelate for the treatment and prevention of postmenopausal osteoporosis. SEARCH STRATEGY: We searched MEDLINE (1996 to March 2005), EMBASE (1996 to week 9 2005), the Cochrane Library (1996 to Issue 1 2005), reference lists of relevant articles and conference proceedings from the last two years. Additional data was sought from authors. SELECTION CRITERIA: We included randomized controlled trials (RCTs) of at least one year duration comparing strontium ranelate versus placebo reporting fracture incidence, bone mineral density (BMD), health related quality of life or safety in postmenopausal women. Treatment (versus prevention) population was defined as women with prevalent vertebral fractures and/or lumbar spine BMD T score < -2.5 SD. DATA COLLECTION AND ANALYSIS: Two reviewers independently determined study eligibility, assessed trial quality and extracted the relevant data. Disagreements were resolved by consensus. RCTs were grouped by dose of strontium ranelate and treatment duration. Where possible, meta-analysis was conducted using the random effects model. MAIN RESULTS: Four trials met the inclusion criteria. Three included a treatment population (0.5 to 2 g of strontium ranelate daily) and one a prevention population (0.125 g, 0.5 g and 1 g daily). A 37% reduction in vertebral fractures (RR 0.63, 95% CI 0.56, 0.71) and a 14% reduction in non-vertebral fractures (RR 0.86, 95% CI 0.75, 0.98) were demonstrated over three years with 2 g of strontium ranelate daily in a treatment population. An increase in BMD was shown at all BMD sites after two to three years in both populations. Lower doses of strontium ranelate were superior to placebo and the highest dose demonstrated the greatest reduction in vertebral fractures and increase in BMD. An increased risk of diarrhea with 2 g of strontium ranelate was found; however, adverse events did not affect the risk of discontinuing treatment nor did it increase the risk of serious side effects, gastritis or death. Additional data suggests that the risk of vascular and nervous system side-effects is slightly increased with taking 2 g of strontium ranelate daily over three to four years. AUTHORS' CONCLUSIONS: There is silver level evidence (www.cochranemsk.org) to support the efficacy of strontium ranelate for the reduction of fractures (vertebral and to a lesser extent non-vertebral) in postmenopausal osteoporotic women and an increase in BMD in postmenopausal women with/without osteoporosis. Diarrhea may occur however, adverse events leading to study withdrawal were not significantly increased with taking 2 g of strontium ranelate daily. Potential vascular and neurological side-effects need to be further explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821 · cited 1×
“Cummings 2002 Cummings SR. Epidemiology and outcomes of osteoporotic fractures.”
BackgroundMarshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Pathogenesis of bone fragility in women and men
Seeman, E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08706-8 · Cited by 909
Robinson, K. A., & Dickersin, K. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.150 · Cited by 833
Cited by
Exercise for preventing and treating osteoporosis in postmenopausal women
Howe, T. E., Shea, B., Dawson, L. J., Downie, F., Murray, A., Ross, C., Harbour, R. T., Caldwell, L. M., & Creed, G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000333.pub2 · Cited by 1,083
Ganda, K., Puech, M., Chen, J. S., Speerin, R., Bleasel, J., Center, J. R., Eisman, J. A., March, L., & Seibel, M. J. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2090-y · Cited by 394
Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 329
The Development of Molecular Biology of Osteoporosis
Gao, Y., Patil, S., & Jia, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158182 · Cited by 116
Vitamin K to prevent fractures in older women: systematic review and economic evaluation
Stevenson, M., Lloyd-Jones, M., & Papaioannou, D. (2009) · Health Technology Assessment · doi:10.3310/hta13450 · Cited by 90
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
Vestergaard, P., Schwartz, F., Rejnmark, L., & Mosekilde, L. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1512-y · Cited by 62
Mohd Effendy, N., Mohamed, N., Muhammad, N., Naina Mohamad, I., & Shuid, A. N. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/125761 · Cited by 55
Metadata
- Authors
- O'Donnell, S., Cranney, A., Wells, G., Adachi, J., & Reginster, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-10-18
- Issue
- 4
- Pages
- CD005326-CD005326
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1769318967
- Cited by
- 179
- References
- 8
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.